Previous Page  3 / 15 Next Page
Information
Show Menu
Previous Page 3 / 15 Next Page
Page Background

allied

academies

Page 52

September 09-10, 2019 | Edinburgh, Scotland

2

nd

Global Summit on

3

rd

International Conference on

Dermatology and Cosmetology

Wound Care, Tissue Repair and Regenerative Medicine

Joint Event

&

Journal of Dermatology Research and Skin Care | Volume 3

Dermatol Res Skin Care, Volume 3

Study on wound healing after cutaneous lesion and reconstructed autologous

pigmented skin dressing (APSD) in nude mice: GLP-study

Jean Christophe Lepivert

1,2

, E Desnouveaux

2

, V Casoli

1,2

and M Cario

1, 2

1

University of Bordeaux, France

2

University Hospital of Bordeaux, France

Authors develop a process of

in vitro

skin reconstruction from

locally anesthetisedpatient’s biopsies. This process is oriented

though applications with patient presenting cutaneous

defect as chronical wounds, burn injuries or congenital

melanocytic nevus. One step of this development process

is reconstructed skin production under Good Laboratory

Practices (GLP). Subsequently, application of Autologous

Pigmented Skin Dressing (APSD) on immunodeficient mouse

model, demonstrates its harmlessness and functionality

with required sanitary characteristics. Clinical results will be

presented in this paper.

Materials and methods:

This technology consists in

reconstructing autologous pigmented skin on a collagen

matrix such as Integra

TM

or Matriderm®. Skin from breast

reductions was taken from the operating room and managed

to the French Blood Establishment (FBE). Keratinocytes,

Melanocytes and fibroblasts were extract from the

biopsy harvested on patient himself and cultured for cells

amplifications. On top of the collagenmatrix, fibroblasts were

seeded to remodel collagen and after this step, keratinocytes

and melanocytes were seeded to produce the epidermal

layer. APSD were produced in 3-5 weeks. The APSD (Test Item

approximately 6 cm

2

) and its culture media was provided by

truck at 18-20°C to testing facility (about 500 km). Testing

facility stored under a 37°C, 5% CO

2

humidified atmosphere

for up to 24 hours. From the Operating room to mice

coverage, skin, cells and reconstructed skin were identified

and traceable. From July 2018 to July 2019, 4 groups of 7mice

were implanted. For each group, 6 mice were treated with

test item and one or two mice with collagen matrix alone as

control. Under general anesthesia defects (3x2 cm) ondorsum

of mice was done and covered with APSD or collagen matrix

alone. This study was conducted according to GLP and EMEA

EMEA/CHMP/410869/2006 31/07/2007) guideline. Wound

healing, clinical behavior, any symptom, tumor development,

and mortality sign were notice every day. Weight, food and

water consumption were notice every week.

Results:

1 mouse did not survive to surgery. Groups 1, 3 and

4 healed well. Follow up demonstrated, a good integration

of APSD with minor retraction and a diffuse pigmentation.

Group 2 healed with multiples milimetric wounds, and during

the healing process, skin retraction appearedwhich increased

with weeks. All collagen matrixes (control group) didn’t heal

and made complete skin retraction for skin closure. Except

one mice which had a nice APSD but loss of weight leading

to sacrificed, the other mice grew up, drank and ate normally

Discussion:

Bioengineered APSD demonstrated enthusiastic

results regarding wound healing. Reconstructed skin could

be easily handled and shipped far from the reconstructed

area. APSD were simply immerged in cultured medium. APSD

groups healed well except for one batch for which the quality

of cells seeded was bad leading to thin APSD.

Conclusion:

Next step will be the clinical trail. The first

selected patients, which will be treated with the autologous-

pigmented skin dressing, could have chronic wounds that

could not be close with traditional treatment as patients with

bad general condition. Phase 1 could be done in 2020 and

time to market calculated for 2025.

Speaker Biography

Jean Christophe Lepivert is currently working as a consultant in University

Hospital of Bordeaux, Bordeaux, France. He is also the head of burn surgery

unit. His research interest lies in plastic, reconstructive and aesthetic

surgery, burns, etc., He also has various research publications in the

international journals.

e:

jc.lepivert@gmail.com